

RPMI 8226 Cells | 300431

General information

Description

RPMI 8226 cells are a human myeloma cell line that was established in 1966 from the peripheral blood of a 61-year-old male patient with multiple myeloma. This cell line was named after the Roswell Park Memorial Institute (RPMI) where it was developed, and the number 8226 denotes its specific catalog number in the cell bank.

The RPMI 8226 cell line is an important model system for studying multiple myeloma and related aspects of plasma cell biology, immunology research, and cancer therapy. RPMI 8226 cells are known to produce and secrete kappa light chains of immunoglobulins, a feature that is often exploited in research studies to investigate antibody production and secretion mechanisms.

RPMI 8226 cells exhibit numerous chromosomal abnormalities, which are typical of multiple myeloma cells. These include translocations, deletions, and amplifications that affect various oncogenes and tumor suppressor genes.

The human myeloma cell line RPMI 8226 are widely used in drug discovery and development research, and have been used to investigate drug resistance pathways and evaluating combination therapies.

In summary, RPMI 8226 cells provide a critical in vitro model for multiple myeloma research, enabling the investigation of the biological and molecular mechanisms underlying this disease and the development of therapeutic strategies.

Organism

Human

Tissue

Peripheral blood

Disease

Multiple Myeloma

Synonyms

RPMI-8226, RPMI.8226, RPMI8226, RPMI no. 8226, RPMI no 8226, RPMI #8226, 8226, RPMI 8226/S, RPMI-8226S, RPMI8226/S, 8226/S, Roswell Park Memorial Institute 8226, GM02132, GM2132, GM 2132, GM02132C, Simpson

Characteristics

Age

61 years

Gender

Male

Morphology

Round cells

Growth properties

Adherent/suspension

Identifiers / Biosafety / Citation

RPMI 8226 Cells | 300431

Citation RPMI 8226 (Cytion catalog number 300431)

Biosafety level 1

Expression / Mutation

Antigen expression HLA Aw19, B15, B37, Cw2

Isoenzymes G6PD, A

Reverse transcriptase Negative

Products Immunoglobulin light chain

Handling

Culture Medium RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO₃ (Cytion article number 820700a)

Medium supplements Supplement the medium with 10% FBS

Passaging solution Accutase

Subculturing Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at room temperature for 10 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium.

Split ratio A ratio of 1:2 to 1:4 is recommended

Seeding density Start new cultures at 5×10^5 viable cells/ml. Subculture at $1-2 \times 10^6$ cells/ml. Maximum cell density is at $1-2 \times 10^6$ cell/ml.

Fluid renewal 2 to 3 times per week

Freezing recovery After thawing allow the cells to recover from the freezing process for at least 24 hours.

RPMI 8226 Cells | 300431

Freeze medium

CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100)

Handling of cryopreserved cultures

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Optionally, skip centrifugation but remove any remaining freezing medium after 24 hours.
7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.
8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Quality control / Genetic profile / HLA

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

RPMI 8226 Cells | 300431

STR profile

Amelogenin: x,x
CSF1PO: 12
D13S317: 11
D16S539: 9
D5S818: 11,13
D7S820: 9,10
TH01: 8
TPOX: 8,11
vWA: 16,18
D3S1358: 16,17
D21S11: 28,29
D18S51: 15,19
Penta E: 16,17
Penta D: 2,2,11
D8S1179: 13
FGA: 19

HLA alleles

A*: 30:01:01, 68:02:01
B*: 15:03:01, 15:10:01
C*: 02:10:01, 03:04:02
DRB1*: 03:01:01, 07:01:01
DQA1*: 02:01:01, 05:01:01
DQB1*: 02:01:01, 02:02:01
DPB1*: 01:01:02G, 13:01:01G
E: 01:01:01, 01:03